G-CSF treatment increases Treg cells in the decidua of women with recurrent pregnancy loss

Abstract

ObjectiveEvaluate the presence of Treg cells inside decidual tissue of pregnancies in recurrent pregnancy loss women treated with G-CSF compared with normal pregnancies.DesignExperimental study using immunohistochemestry.Materials and MethodsTissue specimens of deciduas and trophoblast of 8 abortive first trimester pregnancies obtained from 8 women with recurrent pregnancy loss treated during the pregnancy with G-CSF (1.5mcg/Kg/day from the tenth day after ovulation) were used in an immunohistochemical study for Foxp3. These pregnancies aborted since the embryos showed a chromosomal aneuploidy assessd by trophoblast kariotyping. As controls fifteen samples obtained by fifteen women underwent first trimester voluntary pregnancy termination were used. An avidin-biotin-peroxidase detection system was used for the single and double immunostaining.ResultsIn the decidual samples of women with recurrent pregnancy loss treated with G-CSF a significant increase in the number of cells positive to Foxp3 with respect to controls was observed (24.6+7.9% vs 12.3+3.9%: P<0.01). Also the specific HSCORE showed higher values in the deciduas tissues of G-CSF treated pregnancies with respect to controls (167+46 vs 79+24: P<0.01).ConclusionOur data showed that G-CSF administration in pregnant women with recurrent fetal loss increases the amount of Treg cells in decidua. These findings may explain the effects of G-CSF treatment on pregnancy outcome. ObjectiveEvaluate the presence of Treg cells inside decidual tissue of pregnancies in recurrent pregnancy loss women treated with G-CSF compared with normal pregnancies. Evaluate the presence of Treg cells inside decidual tissue of pregnancies in recurrent pregnancy loss women treated with G-CSF compared with normal pregnancies. DesignExperimental study using immunohistochemestry. Experimental study using immunohistochemestry. Materials and MethodsTissue specimens of deciduas and trophoblast of 8 abortive first trimester pregnancies obtained from 8 women with recurrent pregnancy loss treated during the pregnancy with G-CSF (1.5mcg/Kg/day from the tenth day after ovulation) were used in an immunohistochemical study for Foxp3. These pregnancies aborted since the embryos showed a chromosomal aneuploidy assessd by trophoblast kariotyping. As controls fifteen samples obtained by fifteen women underwent first trimester voluntary pregnancy termination were used. An avidin-biotin-peroxidase detection system was used for the single and double immunostaining. Tissue specimens of deciduas and trophoblast of 8 abortive first trimester pregnancies obtained from 8 women with recurrent pregnancy loss treated during the pregnancy with G-CSF (1.5mcg/Kg/day from the tenth day after ovulation) were used in an immunohistochemical study for Foxp3. These pregnancies aborted since the embryos showed a chromosomal aneuploidy assessd by trophoblast kariotyping. As controls fifteen samples obtained by fifteen women underwent first trimester voluntary pregnancy termination were used. An avidin-biotin-peroxidase detection system was used for the single and double immunostaining. ResultsIn the decidual samples of women with recurrent pregnancy loss treated with G-CSF a significant increase in the number of cells positive to Foxp3 with respect to controls was observed (24.6+7.9% vs 12.3+3.9%: P<0.01). Also the specific HSCORE showed higher values in the deciduas tissues of G-CSF treated pregnancies with respect to controls (167+46 vs 79+24: P<0.01). In the decidual samples of women with recurrent pregnancy loss treated with G-CSF a significant increase in the number of cells positive to Foxp3 with respect to controls was observed (24.6+7.9% vs 12.3+3.9%: P<0.01). Also the specific HSCORE showed higher values in the deciduas tissues of G-CSF treated pregnancies with respect to controls (167+46 vs 79+24: P<0.01). ConclusionOur data showed that G-CSF administration in pregnant women with recurrent fetal loss increases the amount of Treg cells in decidua. These findings may explain the effects of G-CSF treatment on pregnancy outcome. Our data showed that G-CSF administration in pregnant women with recurrent fetal loss increases the amount of Treg cells in decidua. These findings may explain the effects of G-CSF treatment on pregnancy outcome.